α1-Adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume

World Journal of Urology

Volumn 29, Issue 2, 2011, Pages 233-238

  Yokoyama, Osamu ^a   Aoki, Yoshitaka ^a   Tsujimura, Akira ^b   Takao, Tetsuya ^b   Namiki, Mikio ^c   Okuyama, Akihiko ^b  

^a UNIVERSITY OF FUKUI   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

1 Blockers; Nocturia; Polyuria; Sleep

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; NAPHTHALENE DERIVATIVE; PIPERAZINE DERIVATIVE;

AGED; ARTICLE; CLINICAL TRIAL; HUMAN; MALE; MIDDLE AGED; NOCTURIA; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; SLEEP DISORDER; TREATMENT OUTCOME;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; NOCTURIA; PIPERAZINES; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRES; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 79953029280     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0544-4     Document Type: Article

References (25)

1. Middlekoop HA, Smilde-van den Doel DA, Neven AK et al (1996) Subjective sleep characteristics of 1, 485 males and females aged 50-93: effects of sex and age, and related to self-evaluated quality of sleep. J Gerontol A Biol Sci Med Sci 51: M108-M115.
2. van Kerrebroeck P, Abrams P, Chaikin D et al (2002) The standardization of terminology in nocturia: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 21: 179-183.
3. Weiss J, Blaivas JG (2000) Nocturia. J Urol 163: 5-12.
4. Stoevelaar HJ, van De Beek C, Casparie AF et al (1999) Treatment choice for benign prostatic hyperplasia: a matter of urologic preference? J Urol 161: 133-138.
5. Takahashi S, Tajima A, Matsushima H et al (2006) Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int J Urol 13: 15-20.
6. Nishino Y, Masue T, Miwa K et al (2006) Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 97: 747-751.
7. Oh-oka H (2008) Effect of naftopidil on nocturia after failure of tamsulosin. Urology 72: 1051-1055.
8. Ukimura O, Kanazawa M, Fujihara A et al (2008) Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. Int J Urol 15: 1049-1054.
9. Vallancien G, Emberton M, Alcaraz A et al (2008) Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 101: 847-852.
10. Paick JS, Ku JH, Shin JW et al (2006) Alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction. BJU Int 97: 1017-1023.
11. Koseoglu H, Aslan G, Ozdemir I et al (2006) Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy. Urology 67: 1188-1192.
12. Roehrborn CG, Kaplan SA, Jones JS et al (2009) Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 55: 472-481.
13. Bylund DB, Eikenberg DC, Hieble JP et al (1994) International union of pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46: 121-136.
14. Hampel C, Dolber PC, Smith MP et al (2002) Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 167: 1513-1521.
15. 1-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res 63: 254-261.
16. 1d-adrenoceptor. J Urol 174: 370-374.
17. 1-adrenoceptors. Jpn J Pharmacol 79: 447-454.
18. Du Beau CE, Yalla SV, Resnick NM (1995) Implications of the most bothersome prostatism for clinical care and outcomes research. J Am Geriatr Soc 43: 985-992.
19. Asplund R (1995) The nocturnal polyuria syndrome (NPS). Gen Pharmacol 26: 1203-1209.
20. Johnson TM 2nd, Jones K, Williford WO et al (2003) Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 170: 145-148.
21. Asplund R (2004) Nocturia, nocturia polyuria, and sleep quality in the elderly. J Psychosom Res 56: 517-525.
22. Asplund R, Åberg H (1992) Micturition habits of older people. Scand J Urol Nephrol 26: 345-349.
23. 2-adrenoceptors in the regulation of vasopressin release and the cardiovascular system. Endocrinology 114: 1426-1432.
24. De Souza EB, Kuyatt BL (1987) Alpha 1-adrenergic receptors in the neural lobe of the rat pituitary: autoradiographic identification and localization. Endocrinology 120: 2227-2233.
25. Yokoyama O, Yusup A, Oyama N et al (2006) Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol Urodyn 25: 461-477.